Published in Mol Cell Biol on February 01, 2000
Discovery of biological networks from diverse functional genomic data. Genome Biol (2005) 3.73
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol (2013) 1.90
Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones (2003) 1.64
CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol (2004) 1.44
Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation. J Cell Biol (2007) 1.29
Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals. BMC Biochem (2002) 1.24
Cks1 is required for G(1) cyclin-cyclin-dependent kinase activity in budding yeast. Mol Cell Biol (2000) 1.05
Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. Mol Cell Biol (2006) 0.99
Cdc37p is required for stress-induced high-osmolarity glycerol and protein kinase C mitogen-activated protein kinase pathway functionality by interaction with Hog1p and Slt2p (Mpk1p). Eukaryot Cell (2007) 0.99
Identification of Cdc37 as a novel regulator of the stress-responsive mitogen-activated protein kinase. Mol Cell Biol (2003) 0.96
Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors. Br J Pharmacol (2012) 0.89
p50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck. Mol Cell Biol (2000) 0.89
Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene (2013) 0.88
The Hsp110 protein chaperone Sse1 is required for yeast cell wall integrity and morphogenesis. Curr Genet (2008) 0.88
Functions of the Hsp90 chaperone system: lifting client proteins to new heights. Int J Biochem Mol Biol (2013) 0.87
Ydj1 protects nascent protein kinases from degradation and controls the rate of their maturation. Mol Cell Biol (2008) 0.86
Mechanisms regulating the protein kinases of Saccharomyces cerevisiae. Eukaryot Cell (2007) 0.85
Phosphoproteome dynamics of Saccharomyces cerevisiae under heat shock and cold stress. Mol Syst Biol (2015) 0.82
The Schizosaccharomyces pombe Cdc7 protein kinase required for septum formation is a client protein of Cdc37. Eukaryot Cell (2007) 0.78
Alteration of the protein kinase binding domain enhances function of the Saccharomyces cerevisiae molecular chaperone Cdc37. Eukaryot Cell (2007) 0.78
Fission yeast Cdc37 is required for multiple cell cycle functions. Mol Genet Genomics (2003) 0.77
The Gcn2 Regulator Yih1 Interacts with the Cyclin Dependent Kinase Cdc28 and Promotes Cell Cycle Progression through G2/M in Budding Yeast. PLoS One (2015) 0.76
Cdc37 engages in stable, S14A mutation-reinforced association with the most atypical member of the yeast kinome, Cdk-activating kinase (Cak1). Cell Stress Chaperones (2014) 0.75
Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol (1997) 9.87
D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol (1994) 7.35
The selection of S. cerevisiae mutants defective in the start event of cell division. Genetics (1980) 6.19
The specific interaction of the Rous sarcoma virus transforming protein, pp60src, with two cellular proteins. Cell (1981) 4.61
A cellular protein that associates with the transforming protein of Rous sarcoma virus is also a heat-shock protein. Proc Natl Acad Sci U S A (1981) 3.32
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev (1996) 3.26
Mutations in Hsp83 and cdc37 impair signaling by the sevenless receptor tyrosine kinase in Drosophila. Cell (1994) 2.84
Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell (1992) 2.68
Interaction between the Rous sarcoma virus transforming protein and two cellular phosphoproteins: analysis of the turnover and distribution of this complex. Mol Cell Biol (1983) 2.46
The KIN28 gene is required both for RNA polymerase II mediated transcription and phosphorylation of the Rpb1p CTD. J Mol Biol (1995) 2.38
Transit of pp60v-src to the plasma membrane. Proc Natl Acad Sci U S A (1982) 2.29
Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol (1994) 2.19
The Cdk-activating kinase (CAK) from budding yeast. Cell (1996) 2.05
Civ1 (CAK in vivo), a novel Cdk-activating kinase. Cell (1996) 1.99
Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell (1995) 1.92
Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev (1997) 1.88
p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol (1999) 1.83
The selection of amber mutations in genes required for completion of start, the controlling event of the cell division cycle of S. cerevisiae. Genetics (1980) 1.81
A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science (1996) 1.68
Cdc37 is required for association of the protein kinase Cdc28 with G1 and mitotic cyclins. Proc Natl Acad Sci U S A (1995) 1.62
Physical interaction of mammalian CDC37 with CDK4. J Biol Chem (1996) 1.53
Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol (1995) 1.44
Cak1 is required for Kin28 phosphorylation and activation in vivo. Mol Cell Biol (1998) 1.39
Cdc37: a protein kinase chaperone? Trends Cell Biol (1997) 1.37
The yeast CDC37 gene interacts with MPS1 and is required for proper execution of spindle pole body duplication. J Cell Biol (1997) 1.28
Interaction between Cdc37 and Cdk4 in human cells. Oncogene (1997) 1.25
p50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site. J Biol Chem (1998) 1.23
CDC37 is required for p60v-src activity in yeast. Mol Biol Cell (1996) 1.14
The Cak1p protein kinase is required at G1/S and G2/M in the budding yeast cell cycle. Genetics (1997) 1.08
A 50 kilodalton protein associated with raf and pp60(v-src) protein kinases is a mammalian homolog of the cell cycle control protein cdc37. Biochemistry (1997) 0.97
A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature (2000) 10.16
Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. Cell (1986) 8.87
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (1993) 5.31
Crystal structure of cyclin-dependent kinase 2. Nature (1993) 5.21
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
Inhibitory phosphorylation of the APC regulator Hct1 is controlled by the kinase Cdc28 and the phosphatase Cdc14. Curr Biol (1999) 3.96
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 3.53
Insulin-like growth factor II receptor as a multifunctional binding protein. Nature (1987) 3.52
Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci U S A (1992) 3.38
A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell (1994) 3.35
A late mitotic regulatory network controlling cyclin destruction in Saccharomyces cerevisiae. Mol Biol Cell (1998) 3.18
Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature (1995) 3.05
The Polo-related kinase Cdc5 activates and is destroyed by the mitotic cyclin destruction machinery in S. cerevisiae. Curr Biol (1998) 2.92
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev (1995) 2.72
Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell (1992) 2.68
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 2.38
Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol (2000) 2.36
Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol (1999) 2.35
Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol (1998) 2.33
Association of p60c-src with endosomal membranes in mammalian fibroblasts. J Cell Biol (1992) 2.30
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol (1996) 2.21
Pds1 and Esp1 control both anaphase and mitotic exit in normal cells and after DNA damage. Genes Dev (1999) 2.14
Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J (1994) 2.08
Cell cycle control by a complex of the cyclin HCS26 (PCL1) and the kinase PHO85. Science (1994) 1.94
Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell (1995) 1.92
Insulin action is blocked by a monoclonal antibody that inhibits the insulin receptor kinase. Proc Natl Acad Sci U S A (1986) 1.80
Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. J Virol (1984) 1.75
Acute insulin action requires insulin receptor kinase activity: introduction of an inhibitory monoclonal antibody into mammalian cells blocks the rapid effects of insulin. Proc Natl Acad Sci U S A (1987) 1.73
Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol (1994) 1.71
A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science (1996) 1.68
Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J (1994) 1.67
Cdc37 is required for association of the protein kinase Cdc28 with G1 and mitotic cyclins. Proc Natl Acad Sci U S A (1995) 1.62
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Cdc14 activates cdc15 to promote mitotic exit in budding yeast. Curr Biol (2000) 1.58
Kaposi's sarcoma-associated herpesvirus K-bZIP protein is phosphorylated by cyclin-dependent kinases. J Virol (2001) 1.51
Identification of amino acid and nucleotide sequence of the foot-and-mouth disease virus RNA polymerase. Virology (1983) 1.51
Biochemical map of polypeptides specified by foot-and-mouth disease virus. J Virol (1984) 1.46
Suppression of c-Src activity by C-terminal Src kinase involves the c-Src SH2 and SH3 domains: analysis with Saccharomyces cerevisiae. Mol Cell Biol (1993) 1.44
Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol (1995) 1.44
Cak1 is required for Kin28 phosphorylation and activation in vivo. Mol Cell Biol (1998) 1.39
Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta. Proc Natl Acad Sci U S A (1999) 1.39
Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins (1995) 1.35
Foot-and-mouth disease virus immunogenic capsid protein VPT: N-terminal sequences and immunogenic peptides obtained by CNBr and tryptic cleavages. Intervirology (1979) 1.26
Mechanisms of receptor-mediated transmembrane communication. Cold Spring Harb Symp Quant Biol (1986) 1.22
Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology (1988) 1.11
A membrane-anchored cytoplasmic domain of the human insulin receptor mediates a constitutively elevated insulin-independent uptake of 2-deoxyglucose. Mol Endocrinol (1987) 1.11
Purification and crystallization of human cyclin-dependent kinase 2. J Mol Biol (1993) 1.10
Production of p60c-src by baculovirus expression and immunoaffinity purification. Methods Enzymol (1991) 1.09
Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol Cell Biol (2001) 1.09
Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J Gen Virol (1989) 1.06
Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Res (1984) 1.05
Heterologous transmembrane signaling by a human insulin receptor-v-ros hybrid in Chinese hamster ovary cells. Proc Natl Acad Sci U S A (1987) 1.05
Mapping surface structures of the human insulin receptor with monoclonal antibodies: localization of main immunogenic regions to the receptor kinase domain. Biochemistry (1986) 1.04
Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol (1991) 1.04
Foot-and-mouth disease virus: immunogenicity and structure of fragments derived from capsid protein VP and of virus containing cleaved VP. Vet Microbiol (1982) 1.01
Three-dimensional structure of human cyclin H, a positive regulator of the CDK-activating kinase. Nat Struct Biol (1996) 0.99
Immunogenicity of namogram to milligram quantities of inactivated foot-and-mouth disease virus. I. Relative virus-neutralizing potency of guinea pig sera. Appl Microbiol (1969) 0.98
Plate binding assay for monoclonal anti-receptor antibodies. Endocrinology (1985) 0.98
Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies. J Gen Virol (1986) 0.97
The receptor for insulin-like growth factor II mediates an insulin-like response. EMBO J (1987) 0.96
In vivo analysis of the stability and fitness of variants recovered from foot-and-mouth disease virus quasispecies. J Gen Virol (1998) 0.96
Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol (1985) 0.96
Purification and characterization of the receptor for insulin-like growth factor I. Biochemistry (1986) 0.95
Linking functional domains of the human insulin receptor with the bacterial aspartate receptor. Proc Natl Acad Sci U S A (1986) 0.94
Identification of a monoclonal antibody which can distinguish between two distinct species of the type I receptor for insulin-like growth factor. Biochem Biophys Res Commun (1986) 0.93
Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes. Virus Res (1989) 0.90
Antigenic comparison of foot-and-mouth disease virus serotypes with monoclonal antibodies. Virus Res (1986) 0.89
Characterization of anti-idiotypic antibodies generated against foot-and-mouth disease virus neutralizing monoclonal antibodies. Viral Immunol (1989) 0.88
Insulin and insulinlike growth factor receptors and responses in cultured human muscle cells. Am J Physiol (1986) 0.88
Quantitation of the antigenicity and immunogenicity of purified foot-and-mouth disease virus vaccine for swine and steers. Appl Microbiol (1970) 0.86
Identification of virus neutralizing epitopes on naturally occurring variants of type A12 foot-and-mouth disease virus. Virus Res (1989) 0.85
Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems. Vaccine (1993) 0.85
Under arrest at atomic resolution. Nature (1996) 0.84
Analysis of intracellular protein function by antibody injection. Immunol Today (1988) 0.84
Purification and characterization of the human brain insulin receptor. J Biol Chem (1986) 0.83
Antigenic relationships of foot-and-mouth disease virus serotype Asia-1 isolates demonstrated by monoclonal antibodies. Vet Immunol Immunopathol (1992) 0.81
Effects of covalently linked insulin dimers on receptor kinase activity and receptor down regulation. FEBS Lett (1984) 0.81
Interactions of the receptor for insulin-like growth factor II with mannose-6-phosphate and antibodies to the mannose-6-phosphate receptor. Biochem Biophys Res Commun (1987) 0.80
Antibodies elicited by a biosynthetic peptide related to a major immunogenic area of FMDV A12. Viral Immunol (1990) 0.80
Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants. Virus Res (1997) 0.79
IgM antibody--I. Heterogeneity of the component chains of equine anti-lactose antibody. Immunochemistry (1977) 0.79
Analysis of foot-and-mouth disease virus-neutralizing idiotypes from immune bovine and swine with anti-murine idiotype antibody probes. J Immunol (1989) 0.79
Monoclonal antibodies to the insulin receptor. Pharmacol Ther (1985) 0.79
Immunogenicity of nanogram to milligram quantities of inactivated foot-and-mouth disease virus. II. Comparative response of guinea pigs and steers. Proc Annu Meet U S Anim Health Assoc (1968) 0.79
Equine anti-hapten antibody. IX. IgM anti-lactose antibodies. J Immunol (1975) 0.78
Immunoglobulins produced by the antigenized equine fetus. J Reprod Fertil Suppl (1975) 0.78
CAK in TFIIH: crucial connection or confounding coincidence? Biochim Biophys Acta (1996) 0.78
The generation of concentration gradients using electroosmotic flow in micro reactors allowing stereoselective chemical synthesis. Analyst (2001) 0.77
Antibody-induced down-regulation of a mutated insulin receptor lacking an intact cytoplasmic domain. Biochemistry (1987) 0.77
Purification of foot-and-mouth disease virus infection-associated antigen. Proc Annu Meet U S Anim Health Assoc (1978) 0.77
Detection of foot-and-mouth disease virus by competitive ELISA using a monoclonal antibody specific for the 12S protein subunit from six of the seven serotypes. Vet Immunol Immunopathol (1990) 0.77
A proposed role for prostaglandins in the modulation of the relaxation response to urotensin I in isolated rat arteries. Prostaglandins (1981) 0.76
Foot-and-mouth disease virus-neutralizing antibodies induced in mice by anti-idiotypic antibodies. Immunology (1989) 0.76
IgM antibody--II. The isolation and characterization of equine J chain. Immunochemistry (1977) 0.76
The preparation of a series of nitrostilbene ester compounds using micro reactor technology. Analyst (2001) 0.76
Cross-reactive idiotopes among anti-foot and mouth disease virus neutralizing antibodies. Immunology (1993) 0.75